JP2018520668A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520668A5
JP2018520668A5 JP2017565174A JP2017565174A JP2018520668A5 JP 2018520668 A5 JP2018520668 A5 JP 2018520668A5 JP 2017565174 A JP2017565174 A JP 2017565174A JP 2017565174 A JP2017565174 A JP 2017565174A JP 2018520668 A5 JP2018520668 A5 JP 2018520668A5
Authority
JP
Japan
Prior art keywords
compound
seq
tnf superfamily
antibody
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017565174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520668A (ja
JP6951256B2 (ja
Filing date
Publication date
Priority claimed from GBGB1510758.4A external-priority patent/GB201510758D0/en
Application filed filed Critical
Publication of JP2018520668A publication Critical patent/JP2018520668A/ja
Publication of JP2018520668A5 publication Critical patent/JP2018520668A5/ja
Priority to JP2021155537A priority Critical patent/JP7159420B2/ja
Application granted granted Critical
Publication of JP6951256B2 publication Critical patent/JP6951256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017565174A 2015-06-18 2015-10-22 抗体 Active JP6951256B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021155537A JP7159420B2 (ja) 2015-06-18 2021-09-24 抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510758.4A GB201510758D0 (en) 2015-06-18 2015-06-18 Novel TNFa structure for use in therapy
GB1510758.4 2015-06-18
PCT/EP2015/074527 WO2016202414A1 (en) 2015-06-18 2015-10-22 Antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021155537A Division JP7159420B2 (ja) 2015-06-18 2021-09-24 抗体

Publications (3)

Publication Number Publication Date
JP2018520668A JP2018520668A (ja) 2018-08-02
JP2018520668A5 true JP2018520668A5 (enExample) 2018-11-29
JP6951256B2 JP6951256B2 (ja) 2021-10-20

Family

ID=53784155

Family Applications (12)

Application Number Title Priority Date Filing Date
JP2017565114A Active JP7336178B2 (ja) 2015-06-18 2015-10-22 治療における使用のための新規のTNFα構造
JP2017565174A Active JP6951256B2 (ja) 2015-06-18 2015-10-22 抗体
JP2017565155A Active JP6781718B2 (ja) 2015-06-18 2015-10-22 モジュレータアッセイ
JP2017565173A Active JP6659030B2 (ja) 2015-06-18 2015-10-22 作用機構
JP2017565189A Active JP6948954B2 (ja) 2015-06-18 2015-10-22 抗体エピトープ
JP2019154528A Active JP6752344B2 (ja) 2015-06-18 2019-08-27 作用機構
JP2020174314A Pending JP2021038222A (ja) 2015-06-18 2020-10-16 モジュレータアッセイ
JP2021020352A Pending JP2021109880A (ja) 2015-06-18 2021-02-12 治療における使用のための新規のTNFα構造
JP2021095909A Abandoned JP2021153592A (ja) 2015-06-18 2021-06-08 抗体エピトープ
JP2021155537A Active JP7159420B2 (ja) 2015-06-18 2021-09-24 抗体
JP2023001089A Pending JP2023052250A (ja) 2015-06-18 2023-01-06 モジュレータアッセイ
JP2023046164A Pending JP2023100010A (ja) 2015-06-18 2023-03-23 治療における使用のための新規のTNFα構造

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017565114A Active JP7336178B2 (ja) 2015-06-18 2015-10-22 治療における使用のための新規のTNFα構造

Family Applications After (10)

Application Number Title Priority Date Filing Date
JP2017565155A Active JP6781718B2 (ja) 2015-06-18 2015-10-22 モジュレータアッセイ
JP2017565173A Active JP6659030B2 (ja) 2015-06-18 2015-10-22 作用機構
JP2017565189A Active JP6948954B2 (ja) 2015-06-18 2015-10-22 抗体エピトープ
JP2019154528A Active JP6752344B2 (ja) 2015-06-18 2019-08-27 作用機構
JP2020174314A Pending JP2021038222A (ja) 2015-06-18 2020-10-16 モジュレータアッセイ
JP2021020352A Pending JP2021109880A (ja) 2015-06-18 2021-02-12 治療における使用のための新規のTNFα構造
JP2021095909A Abandoned JP2021153592A (ja) 2015-06-18 2021-06-08 抗体エピトープ
JP2021155537A Active JP7159420B2 (ja) 2015-06-18 2021-09-24 抗体
JP2023001089A Pending JP2023052250A (ja) 2015-06-18 2023-01-06 モジュレータアッセイ
JP2023046164A Pending JP2023100010A (ja) 2015-06-18 2023-03-23 治療における使用のための新規のTNFα構造

Country Status (16)

Country Link
US (12) US11022614B2 (enExample)
EP (8) EP3960759A1 (enExample)
JP (12) JP7336178B2 (enExample)
KR (2) KR20180048571A (enExample)
CN (6) CN108290945B (enExample)
AU (2) AU2015398984B2 (enExample)
CA (4) CA2988723A1 (enExample)
CL (2) CL2017003189A1 (enExample)
EA (4) EA201890080A1 (enExample)
ES (5) ES2948915T3 (enExample)
GB (1) GB201510758D0 (enExample)
IL (2) IL256099B2 (enExample)
MX (2) MX2017015757A (enExample)
PL (4) PL3311171T3 (enExample)
PT (4) PT3311169T (enExample)
WO (5) WO2016202411A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
CN107454905B (zh) 2015-03-31 2023-04-28 索里索制药公司 多肽
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Tnf信號傳遞之三環調節劑
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
TW201706258A (zh) 2015-04-17 2017-02-16 艾伯維有限公司 作為tnf信號傳遞調節劑之吲唑酮
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR102446529B1 (ko) * 2017-01-10 2022-09-23 에테하 취리히 세포 보호 화합물 및 이의 용도
MX2021015761A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Polipeptidos.
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
JP7561364B2 (ja) * 2020-04-30 2024-10-04 国立大学法人東北大学 蛍光偏光免疫分析法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
DE3843534A1 (de) 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
IT1249708B (it) 1991-09-23 1995-03-09 Tecnogen Scpa Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1993014083A1 (en) 1992-01-09 1993-07-22 Janssen Pharmaceutica N.V. Pharmaceutically active substituted benzimidazole derivatives
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU6001094A (en) 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440613C1 (de) 1994-11-14 1996-07-25 Leica Ag Vorrichtung und Verfahren zur Detektion und Demodulation eines intensitätsmodulierten Strahlungsfeldes
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CN1204230A (zh) 1997-12-08 1999-01-06 李建安 一种手提电话机用防护罩及其制做方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
GB9828628D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7101974B2 (en) * 2000-03-02 2006-09-05 Xencor TNF-αvariants
WO2002018540A2 (en) 2000-09-01 2002-03-07 Biogen, Inc. Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications
DE60214392T2 (de) 2001-06-05 2008-01-17 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 1,4-Disubstituierte Benzo-kondensierte Cycloalkyl-Harnstoffverbindungen
US6632810B2 (en) 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
JP2003040888A (ja) 2001-07-30 2003-02-13 Sankyo Co Ltd イミダゾール誘導体
CA2494276A1 (en) 2002-08-01 2004-02-12 Wyeth Methods and reagents relating to inflammation and apoptosis
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
AU2004235875A1 (en) 2003-05-09 2004-11-18 Pharmexa A/S Immunogenic human TNF alpha analogues with reduced cytotoxicity and methods of their preparation
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN1849138B (zh) 2003-07-15 2011-11-30 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
TW200526780A (en) 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗TNF-α之抗體及其用途
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US20090035225A1 (en) 2007-08-03 2009-02-05 Alcon Research, Ltd. RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
RU2011151260A (ru) * 2008-11-20 2013-06-20 Панацеа Биотек Лтд. Пептиды, ингибирующие фактор некроза опухолей альфа, и их применения
JP2010172307A (ja) 2009-01-30 2010-08-12 Saitama Medical Univ 関節リウマチに対する可溶性TNFα/LTαレセプター薬の薬効予測方法、及び薬効予測装置
US20120094935A1 (en) 2009-04-09 2012-04-19 West Anthony P Methods for creating or identifying compounds that bind tumor necrosis factor alpha
CA2758964A1 (en) 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anti-tnf-.alpha. antibodies and their uses
CN102958537B (zh) 2010-04-07 2015-09-16 Abbvie公司 TNF-α结合蛋白
US8377441B2 (en) 2010-08-03 2013-02-19 National Cheng Kung University Treating breast cancer with anti-IL-19 antibody
CA2853974C (en) 2010-10-30 2020-11-10 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
US20140112929A1 (en) 2011-06-17 2014-04-24 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
EP2741760A2 (en) 2011-08-12 2014-06-18 B.S.R.C. "Alexander Fleming" Tnf superfamily trimerization inhibitors
US9550737B2 (en) * 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
BR112015000675B1 (pt) 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
WO2014040076A1 (en) 2012-09-10 2014-03-13 Xencor Methods of treating neurological diseases
AU2014215639B2 (en) 2013-01-25 2017-03-23 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease
CN105307771B (zh) 2013-03-12 2018-11-13 阿内洛技术股份有限公司 催化快速热解催化剂的再生
EP3022229A1 (en) * 2013-07-15 2016-05-25 Novo Nordisk A/S Antibodies that bind urokinase plasminogen activator
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN105814022B (zh) 2013-12-09 2018-09-28 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合的二环杂芳族衍生物
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321731D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321749D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN107108672B (zh) 2014-10-03 2019-11-08 Ucb生物制药私人有限公司 稠合的五环咪唑衍生物
TWI774028B (zh) 2015-01-30 2022-08-11 學校法人埼玉醫科大學 抗alk2抗體及其用途
EA201792054A1 (ru) 2015-03-18 2018-01-31 Бристол-Майерс Сквибб Компани Гетероциклические соединения, применимые в качестве ингибиторов tnf
KR102654709B1 (ko) 2015-03-18 2024-04-03 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
MX2017011433A (es) 2015-03-18 2017-11-10 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
TW201706258A (zh) 2015-04-17 2017-02-16 艾伯維有限公司 作為tnf信號傳遞調節劑之吲唑酮
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Tnf信號傳遞之三環調節劑
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201509888D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509885D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509893D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
KR102679517B1 (ko) 2015-08-03 2024-06-27 브리스톨-마이어스 스큅 컴퍼니 Tnf 알파의 조정제로서 유용한 시클릭 화합물
BR112018001960A2 (pt) 2015-08-03 2018-09-18 Bristol-Myers Squibb Company compostos heterocíclicos úteis como moduladores de tnf alfa
BR112018069936A2 (pt) 2016-04-01 2019-02-05 Sanofi Sa derivados de imidazol pentacíclicos fundidos como moduladores de atividade do tnf
US10654861B2 (en) 2016-04-01 2020-05-19 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity
CA3018907A1 (en) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity
CA3018992A1 (en) 2016-04-01 2017-10-05 Ucb Biopharma Sprl Fused hexacyclic imidazole derivatives as modulators of tnf activity
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Similar Documents

Publication Publication Date Title
JP2018520668A5 (enExample)
AU2021203783B2 (en) Novel CD47 Monoclonal Antibodies and Uses Thereof
JP2018532383A5 (enExample)
JP2017535257A5 (enExample)
JP2018520657A5 (enExample)
JP2017505125A5 (enExample)
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2020522261A5 (enExample)
JP2021500916A5 (enExample)
IL261666B2 (en) Binding proteins and methods of use thereof
JP2018511319A5 (enExample)
JP2013506428A5 (enExample)
JP2018508462A5 (enExample)
JP2015535828A5 (enExample)
JP2017524725A5 (enExample)
CN104903352A (zh) 多价结合蛋白组合物
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
JP2015503909A5 (enExample)
EP2928919A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP2016519650A5 (enExample)
JP2013500941A5 (enExample)
JP2020530272A5 (enExample)
RU2014118739A (ru) Способы ингибирования роста опухоли путем антагонизирования ил-6 рецептора
JP2018525333A5 (enExample)
JP2010501164A5 (enExample)